Maximize the Potential of Spent Hydroprocessing Catalysts
A new approach is helping reduce waste, recover value and deliver on sustainability goals
The Trump Tariffs
China’s chemical industry is diversifying markets, boosting innovation, and strengthening supply chains to counter US tariffs and maintain export resilience.
Fostering Innovation and Collaboration
Valerie Diele-Braun, CEO of IMCD, shares her vision for sustainability, global expansions, and strategic direction in an exclusive CHEManager International interview.
Making Waves
Global water scarcity is now urgent due to climate change, population growth, and unsustainable practices. 700 million people could be displaced by 2030, warns UNICEF, especially in water-intensive industries like personal care, textiles, food production, and paint.
19.03.2025 • Topics • Digitalization
From Data Silos to a Digital Future
Chemical producers in Germany are grappling with rising costs, high energy prices, global competition, and an impending knowledge gap due to demographic shifts. Kuraray, a global leader in specialty chemicals, is addressing these challenges with a comprehensive digitalization strategy.
Substances of Concern
The EU Chemicals Strategy for Sustainability (CSS) highlights the shift to a hazard-centric approach in EU chemical regulation, emphasizing 'Substance of Concern' over risk-based measures.
The Future of Demand for Chemicals
The chemical industry is shifting to sustainability-related products, with demand growing 4.5 times faster than conventional ones. Companies must revise their market strategies to capitalize on this opportunity.
17.02.2025 • Topics • Digitalization
Innovation at the Intersection of AI
John Banovetz, Chief Technology Officer at 3M, on the role of digital transformation in realizing the company's goals.
17.01.2025 • Webinar
Photoredox Catalysis
Free Virtual Event on February 11, 2025 11:00 am EDT | 17:00 pm CET
Circular Solutions
The path to a sustainable, net-zero future for the chemical industry is paved with challenges – and also opportunities.
Excellence in Pharmaceutical Distribution and the Critical Role of Good Distribution Practice (GDP)
Companies in pharma can improve their raw material sourcing through a strategic partnership with a distributor.
11.11.2024 • Topics • Digitalization
Artificial Intelligence – a Revolution for Innovation?
Artificial intelligence (AI) has made groundbreaking progress in recent years, particularly through innovations in machine learning and neural networks. These developments are largely driven by deep learning technologies, which enable the recognition of complex data patterns and the achievement of human-like performance in areas such as speech recognition, image processing, and decision-making.
Innovative Maintenance Strategies: Balancing Costs and Enhancing Value
Interview with Michiel van den Boomen, Vice-President of Efeso Management Consultants.
Expert Statement: Frank Ferrante, Cambrex
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Insights into Biologics and Pharmaceutical Manufacturing
Bill Humphries, CEO of Alcami, shares his vision for the future, discussing dynamic market trends and the company’s commitment to innovation. Under his leadership, Alcami is poised to redefine the pharmaceutical and biotechnology landscape, focusing on cutting-edge solutions and navigating global complexities. This conversation highlights Alcami’s strategic direction, accomplishments, and upcoming challenges.
Increasing Gap in Biotech Venture Funding
Consulting firm BCG has evaluated the effectiveness of biotech innovation centers in Europe and the USA. Adolphs explains what is lacking in Germany in particular.
The Evolution of the CDMO Industry
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine. CHEManager asked executives and industry experts from a broad range of CDMOs to share their views on how their companies are dealing with this changing economic environment and the resulting opportunities and challenges.
Flow Chemistry — The Right Tool for CDMOs
For CDMOs, the adoption of flow chemistry can provide a competitive advantage by improving efficiency, safety and quality, while reducing costs and development times.
Uncovering Potential
Interview with Olivier Lambrechts, executive leadership team member and president NCE at Arxada.
Chemical Labor Productivity Challenge
The chemical industry faces acute labor shortages because the talent pool is shrinking, but the industry remains heavily reliant on manual work. Therefore, realizing labor productivity potential will be decisive for business continuity and future growth.
Expert Statement: Martin Meeson, Axplora
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Victor Swint, Formulated Solutions
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Akhil Ravi, Aurigene Pharmaceutical Services
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Yu Lu, WuXi STA
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Jordi Robinson, Navin Molecular
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Greg Behar, Recipharm
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Alex Del Priore, Syngene
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Chad Telgenhof, Sterling Pharma Solutions
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Thomas Otto and Peter Soelkner, Vetter
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Rohtash Kumar, Veranova
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Tom Wilson, Pfizer
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Davuluri Saharsh Rao, Neuland Labs
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Federico Pollano, Rentschler
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Prasad Raje, LGM Pharma
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Christoph Schaffrath, Lanxess
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
